Literature DB >> 33985820

FXR agonists for NASH: How are they different and what difference do they make?

Claus Kremoser1.   

Abstract

Entities:  

Keywords:  Cilofexor; EDP-305; FXR agonist; MET-409; NASH; Obeticholic acid; Tropifexor; histopathology; liver fibrosis; pruritus

Year:  2021        PMID： 33985820     DOI： 10.1016/j.jhep.2021.03.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  13 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 2.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 3.  An Update on the Chemokine System in the Development of NAFLD.

Authors:  Naoto Nagata; Guanliang Chen; Liang Xu; Hitoshi Ando
Journal:  Medicina (Kaunas)       Date:  2022-06-05       Impact factor: 2.948

Review 4.  Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.

Authors:  Yong-Yu Yang; Li Xie; Ning-Ping Zhang; Da Zhou; Tao-Tao Liu; Jian Wu
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

5.  Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.

Authors:  Tianwei Zhang; Shanshan Feng; Jiahuan Li; Zhitao Wu; Qiangqiang Deng; Wei Yang; Jing Li; Guoyu Pan
Journal:  Arch Toxicol       Date:  2022-03-10       Impact factor: 6.168

6.  Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH.

Authors:  Yu-Feng Li; Zhi-Fu Xie; Qian Song; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2022-02-01       Impact factor: 7.169

7.  Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling.

Authors:  Yun Li; Huiqin Hou; Xianglu Wang; Xin Dai; Wanru Zhang; Qiang Tang; Yue Dong; Chen Yan; Bangmao Wang; Zhengxiang Li; Hailong Cao
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 8.  Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.

Authors:  Boyan Zhang; Folkert Kuipers; Jan Freark de Boer; Jan Albert Kuivenhoven
Journal:  J Clin Med       Date:  2021-12-21       Impact factor: 4.241

Review 9.  Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.

Authors:  Veronika A Prikhodko; Natalia N Bezborodkina; Sergey V Okovityi
Journal:  Biomedicines       Date:  2022-01-26

10.  Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Albrecht Boehlig; Florian Gerhardt; David Petroff; Florian van Boemmel; Thomas Berg; Valentin Blank; Thomas Karlas; Johannes Wiegand
Journal:  Biomedicines       Date:  2022-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.